Trials / Recruiting
RecruitingNCT06776952
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Evopoint Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Days – 70 Days
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XNW5004 ; Chidamide placebo | XNW5004 + Chidamide placebo |
| DRUG | XNW5004 placebo; Chidamide | XNW5004 placebo + Chidamide |
Timeline
- Start date
- 2025-04-10
- Primary completion
- 2028-01-01
- Completion
- 2028-04-01
- First posted
- 2025-01-15
- Last updated
- 2026-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06776952. Inclusion in this directory is not an endorsement.